Medication use during end-of-life care in a palliative care centre

International Journal of Clinical Pharmacy

Volumn 37, Issue 5, 2015, Pages 767-775

  Masman, Anniek D ^a,b   van Dijk, Monique ^a   Tibboel, Dick ^a   Baar, Frans P M ^a,b   Mathôt, Ron A A ^a,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Palliative Care Centre   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Drug therapy; Drug utilization; Netherlands; Palliative care; Pharmaceutical preparations; Prescriptions; Terminal care

Indexed keywords

DEXAMETHASONE; FENTANYL; HALOPERIDOL; MACROGOL; METOCLOPRAMIDE; METOPROLOL; MIDAZOLAM; MORPHINE; PARACETAMOL; RABEPRAZOLE; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE; TEMAZEPAM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COHORT ANALYSIS; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CENTER; HOSPITAL ADMISSION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERMINAL CARE; VERY ELDERLY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG UTILIZATION; EPIDEMIOLOGY; NEOPLASMS; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TERMINAL CARE;

EID: 84943200164     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-015-0094-3     Document Type: Article

References (48)

1. Statistics Netherlands. Causes of death. 2011. http://statline.cbs.nl/StatWeb/publication/?DM=SLEN&PA=7052ENG&D1=0,7&D2=0&D3=0&D4=0,10,20,30,40,50,60-61&LA=EN&VW=T. Accessed Nov 2014.
2. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag. 2007;34:94–104.
3. De Lima L. International association for hospice and palliative care list of essential medicines for palliative care. Ann Oncol. 2007;18:395–9.
4. Good PD, Cavenagh JD, Currow DC, Woods DA, Tuffin PH, Ravenscroft PJ. What are the essential medications in pallative care?—a survey of Australian palliative care doctors. Aust Fam Physician. 2006;35:261–4.
5. IKNL. Guidelines for diagnosis and treatment in palliative care. 2010. www.pallialine.nl. Accessed Nov 2014.
6. Twycross R, Wilcock A. PCF4: Palliative Care Formulary. 4th ed. Nottingham: Palliativedrugs.com Ltd; 2011. ISBN 978-0-9552547-5-8.
7. McNicol E, Strassels S, Goudas L, Lau J, Carr D. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol. 2004;22:1975–92.
8. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol. 2012;51:996–1008.
9. Wiffen PJ and McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007; (4): CD003868.
10. Lonergan E, Britton AM, Luxenberg J and Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007; (2): CD005594.
11. Candy B, Jackson KC, Jones L, Leurent B, Tookman A and King M. Drug therapy for delirium in terminally ill adult patients. Cochrane Database Syst Rev. 2012; 11: CD004770.
12. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.
13. Mihelic RA. Pharmacology of palliative medicine. Semin Oncol Nurs. 2005;21:29–35.
14. Strouse TB. Pharmacokinetic drug interactions in palliative care: focus on opioids. J Palliat Med. 2009;12:1043–50.
15. Atkinson CV, Kirkham SR. Unlicensed uses for medication in a palliative care unit. Palliat Med. 1999;13:145–52.
16. Toscani F, Di Giulio P, Campi R, Pellerin I, De Luca A, Casale G. Off-label prescriptions in Italian hospices: a national survey. J Pain Symptom Manage. 2009;38:365–71.
17. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med. 2004;18:100–7.
18. Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, et al. Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer. 2013;21:1003–11.
19. Sera L, McPherson ML, Holmes HM. Commonly prescribed medications in a population of hospice patients. Am J Hosp Palliat Care. 2014;31:126–31.
20. McLean S, Sheehy-Skeffington B, O’Leary N, O’Gorman A. Pharmacological management of co-morbid conditions at the end of life: is less more? Ir J Med Sci. 2013;182:107–12.
21. Curtis EB, Walsh TD. Prescribing practices of a palliative care service. J Pain Symptom Manage. 1993;8:312–6.
22. Riechelmann RP, Krzyzanowska MK, O’Carroll A, Zimmermann C. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer. 2007;15:1407–12.
23. Currow DC, Stevenson JP, Abernethy AP, Plummer J, Shelby-James TM. Prescribing in palliative care as death approaches. J Am Geriatr Soc. 2007;55:590–5.
24. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, 2003.
25. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004;18:195–201.
26. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.
27. Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? Cancer. 2004;101:1473–7.
28. Ensor BR, Middlemiss TP. Benchmarking opioids in the last 24 hours of life. Intern Med J. 2011;41:179–85.
29. Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Hanson J, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manag. 1995;10:348–55.
30. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manag. 2001;21:282–9.
31. Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med. 2003;163:341–4.
32. Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. Intern Med J. 2005;35:512–7.
33. Farriols C, Ferrandez O, Planas J, Ortiz P, Mojal S, Ruiz AI. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manag. 2012;43:945–52.
34. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000;160:786–94.
35. Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care–Part III: dyspnea and delirium. J Palliat Med. 2006;9:422–36.
36. Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. Does this patient have delirium?: value of bedside instruments. JAMA. 2010;304:779–86.
37. Leonard MM, Nekolaichuk C, Meagher DJ, Barnes C, Gaudreau JD, Watanabe S, et al. Practical assessment of delirium in palliative care. J Pain Symptom Manag. 2014;48:176–90.
38. Ellershaw J. Care of the dying: what a difference an LCP makes! Palliat Med. 2007;21:365–8.
39. Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manag. 1990;5:259–61.
40. Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, Bonnabry P. Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliat Med. 2005;19:208–19.
41. Medicines Evaluation Board; the Dutch data bank for human medicines. 2014. http://www.cbg-meb.nl/CBG/en/human-medicines/geneesmiddeleninformatiebank/default.htm. Accessed Nov 2014.
42. Radbruch L, Trottenberg P, Elsner F, Kaasa S, Caraceni A. Systematic review of the role of alternative application routes for opioid treatment for moderate to severe cancer pain: an EPCRC opioid guidelines project. Palliat Med. 2011;25:578–96.
43. de Sousa E, Jepson BA. Midazolam in terminal care. Lancet. 1988;1:67–8.
44. Bleasel MD, Peterson GM, Dunne PF. Plasma concentrations of midazolam during continuous subcutaneous administration in palliative care. Palliat Med. 1994;8:231–6.
45. Stiefel F, Fainsinger R, Bruera E. Acute confusional states in patients with advanced cancer. J Pain Symptom Manag. 1992;7:94–8.
46. Olofsson SM, Weitzner MA, Valentine AD, Baile WF, Meyers CA. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Cancer. 1996;4:351–7.
47. LeGrand SB. Delirium in palliative medicine: a review. J Pain Symptom Manag. 2012;44:583–94.
48. Caraceni A, Simonetti F. Palliating delirium in patients with cancer. Lancet Oncol. 2009;10:164–72.